Top line results from Novo Nordisk A/S’s groundbreaking Phase III clinical trial on its Wegovy linking treatment to a significant cardiovascular benefit in obese subjects may tip the balance toward better coverage among US commercial payers already leaning that way. But it probably won’t lead to a wholesale embrace of obesity drugs yet.
Novo’s large SELECT trial showed use of Wegovy (semaglutide) led to a 20% reduction in major adverse cardiovascular events for...







